Added to YB: 2026-08-19
Pitch date: 2026-08-14
HLN [neutral]
Haleon plc
Author Info
No bio for this author
Company Info
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Market Cap
GBP 31.3B
Pitch Price
N/A
Price Target
N/A
Dividend
2.05%
EV/EBITDA
13.37
P/E
19.64
EV/Sales
3.48
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 14/8/2026 - HLN – Bond moves
HLN (update): Launched $2bn cash tender for 3.375% notes due Mar 2027, funded by new $2bn three-tranche issue (2029/2031/2036) at 5.00% WACC, adding ~$32.5m annual interest—immaterial vs £32bn mkt cap—terming out maturities. Net debt cut to £7.5bn from £10.3bn since '22 IPO. Trades 16.3x fwd PE.
Read full article (1 min)